Research Article DevelopmentofUVSpectrophotometricProceduresfor DeterminationofAmlodipineandCelecoxibinFormulation: UseofScalingFactortoImprovetheSensitivity MaheshAttimarad , 1 KatharigattaNarayanaswamyVenugopala , 1,2 BandarE.Aldhubiab , 1 AnroopBalachandranNair, 1 NagarajaSreeHarsha , 1 ShinuPottathil, 3 andSabahH.Akrawi 1 1 Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf, Al-Ahsa 31982, Saudi Arabia 2 Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa 3 Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf, Al-Ahsa 31982, Saudi Arabia Correspondence should be addressed to Mahesh Attimarad; mattimarad@kfu.edu.sa Received 30 June 2019; Revised 18 September 2019; Accepted 1 October 2019; Published 7 December 2019 Academic Editor: Sarfaraz Ahmed Mahesar Copyright © 2019 Mahesh Attimarad et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. FDA has recently approved a new fixed-dose combination of amlodipine besylate (AMD) and celecoxib (COX) for the treatment of hypertension and osteoarthritis. No analytical method has been reported for analysis of these two analytes so far. Hence, to monitor the quality and quantity in the formulation of AMD and COX a simple, accurate, precise, economical, and eco-friendly spectroscopic analytical method has been established. e first method involves the determination of AMD and COX by the first derivative UV spectroscopic method with scaling factor 10. However, the second method was based on the direct measurement of UV absorbance of AMD at 364.3 nm and ratio first derivative UV spectroscopic method for COX. Both methods showed good linearity in the range of 5 to 40 μg/ml for COX, whereas AMD showed linearity in the range of 0.5 to 10 μg/ml in first derivative method with scaling factor 10 and 1 to 10 μg/ml in the second method with good correlation coefficient (R 2 > 0.998). Both the methods were validated for LOD, LOQ, accuracy, precision, recovery studies, and stability as per the ICH guidelines, and the validated results were well within the acceptable range. Both the methods were successfully utilized for the determination of AMD and COX in the presence of each other in the formulation, and statistically compared between the proposed methods. erefore, the proposed procedures can be utilized for regular quality control studies. 1.Introduction Hypertension and osteoarthritis (OA) are major health problems in the middle- and old-age population. Generally, these two diseases coexist, and 40% of OA patients were diagnosed for hypertension [1]. However, the treatment for these two diseases is challenging, because of the adverse effects of NSAIDs on the blood pressure [2]. Nevertheless, celecoxib (COX, Figure 1(a)) was found to be a better choice because it has low risk on blood pressure than ibuprofen, naproxen, or other NSAIDs, and COX has low gastroin- testinal and kidney toxicity [3, 4]. Hence, FDA has recently approved a fixed-dose combination of calcium channel blocker, amlodipine besylate, and selective COX-2 inhibitor, celecoxib, for the treatment of hypertension and OA [5]. Amlodipine besylate (AMD, Figure 1(b)), a long-acting calcium channel blocker, is a dihydropyridine derivative extensively used for the management of hypertension and angina pectoris [6]. Several analytical methods were de- scribed in the literature for quantification of AMD alone and Hindawi Journal of Spectroscopy Volume 2019, Article ID 8202160, 10 pages https://doi.org/10.1155/2019/8202160